US EditionPublished • loading... • Updated
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety ...
Summary by Enid News & Eagle
2 Articles
2 Articles
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Pacira BioSciences (NASDAQ:PCRX)
- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
